29.07.2010 • News • Sanofi • Genzyme • Mergers & Acquisitions (M&A)

Sanofi to Press Ahead on Genzyme Bid

France's Sanofi-Aventis plans to press ahead with a formal offer for Genzyme after its informal overture failed to strike interest, a source familiar with the situation said on Wednesday.

The board of Sanofi met in Paris on Wednesday and voted to make a formal offer for Genzyme, though details of the proposal were not immediately available. Sanofi, which is scheduled to report second-quarter earnings on Thursday, declined to comment.

Genzyme could not be immediately reached for comment.

Reports that Sanofi was making a run at Genzyme surfaced on Friday, sending the U.S. company's shares up more than 15% as investors figured the company would garner a hefty premium for its portfolio of expensive treatments for rare genetic disorders and a pipeline of drugs in development.

Some company watchers say Genzyme shareholders may be willing to accept a price of $70 to $80 per share, particularly newer investors who were drawn to the company when it was targeted by activist investor Carl Icahn.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.